Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis.

Atrial Fibrillation / complications Drug-Eluting Stents / adverse effects Humans Percutaneous Coronary Intervention / adverse effects Prosthesis Design Risk Factors Stents / adverse effects Treatment Outcome
Antithrombotic therapy Atrial fibrillation Meta-analysis Stent Systematic review

Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
11 2020
Historique:
received: 11 04 2020
revised: 29 06 2020
accepted: 06 07 2020
pubmed: 21 7 2020
medline: 22 6 2021
entrez: 21 7 2020
Statut: ppublish

Résumé

A systematic review and meta-analysis was performed to evaluate the safety and efficacy of drug-eluting stents (DES) vs bare-metal stents (BMS) in atrial fibrillation (AF) patients. We systematically searched 5 engines until May 2019 for cohort studies and randomized controlled trials (RCTs). Primary outcomes were major bleeding and major adverse cardiac events (MACE) including cardiac death, myocardial infarction, target vessel revascularization (TVR) or stent thrombosis. Effects of inverse variance random meta-analyses were described with relative risks (RR) and their 95% confidence intervals (CI). We also stratified analyses by type (triple [TAT] vs dual [DAT]) and duration (short-vs long-term) of antithrombotic therapy. Ten studies (3 RCTs; 7 cohorts) including 10,353 patients (DES: 59.6%) were identified. DES did not show higher risk of major bleeding than BMS (5.6% vs 6.9%, RR 1.07; 95%CI, 0.89-1.28, p = 0.47; I In patients with AF undergoing PCI, DES had similar rate of major bleeding and MACE than BMS. DAT seems to be a safer antithrombotic therapy compared with TAT.

Identifiants

DOI: 10.1016/j.thromres.2020.07.010 PMID: 32688097
pubmed: 32688097
pii: S0049-3848(20)30301-7
doi: 10.1016/j.thromres.2020.07.010
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-135

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Antonia Sambola (A)

Department of Cardiology and University Hospital Vall d'hebron, Universitat Autònoma, Barcelona, Spain; Research Institute, University Hospital Vall d'hebron, CIBERCV, Barcelona, Spain. Electronic address: asambola@vhebron.net.

Pau Rello (P)

Department of Cardiology and University Hospital Vall d'hebron, Universitat Autònoma, Barcelona, Spain; Research Institute, University Hospital Vall d'hebron, CIBERCV, Barcelona, Spain.

Toni Soriano (T)

Department of Cardiology and University Hospital Vall d'hebron, Universitat Autònoma, Barcelona, Spain; Research Institute, University Hospital Vall d'hebron, CIBERCV, Barcelona, Spain.

Deepak L Bhatt (DL)

Brigham and Women's Hospital Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA.

Vinay Pasupuleti (V)

MedErgy HealthGroup, Inc., Yardley, PA, USA.

Christopher P Cannon (CP)

Brigham and Women's Hospital Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA.

C Michael Gibson (CM)

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Willem J M Dewilde (WJM)

Department of Cardiology, Saint Antonius Hospital, Nieuwegein, the Netherlands.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Eric D Peterson (ED)

Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.

K E Juhani Airaksinen (KEJ)

Turku University Hospital and University of Turku, Turku, Finland.

Tuomas Kiviniemi (T)

Brigham and Women's Hospital Heart and Vascular Center, and Harvard Medical School, Boston, MA, USA; Turku University Hospital and University of Turku, Turku, Finland.

Laurent Fauchier (L)

Division of Cardiology, Pôle Coeur Thorax Vasculaire, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine de l'Université François Rabelais, Tours, France.

Lorenz Räber (L)

Department of Cardiology, Bern University Hospital, Bern, Switzerland.

Juan M Ruiz-Nodar (JM)

Hospital General Universitario de Alicante, Alicante, Spain.

Maciej Banach (M)

Department of Hypertension, Medical University of Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.

Héctor Bueno (H)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Adrian V Hernandez (AV)

University of Connecticut/Hartford Hospital Evidence-based Practice Center, Hartford, CT, USA; School of Medicine, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru. Electronic address: adrian.hernandez-diaz@uconn.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Troubles du rythme cardiaque › Fibrillation auriculaire › Safety and efficacy of drug eluting stents vs...
questionsmedicales.fr › Équipement et fournitures › Prothèses et implants › Endoprothèses › Endoprothèses à élution de substances › Safety and efficacy of drug eluting stents vs...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Safety and efficacy of drug eluting stents vs...
questionsmedicales.fr › Procédures de chirurgie opératoire › Interventions chirurgicales mini-invasives › Procédures endovasculaires › Intervention coronarienne percutanée › Safety and efficacy of drug eluting stents vs...
questionsmedicales.fr › Équipement et fournitures › Prothèses et implants › Conception de prothèse › Safety and efficacy of drug eluting stents vs...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Safety and efficacy of drug eluting stents vs...
questionsmedicales.fr › Équipement et fournitures › Prothèses et implants › Endoprothèses › Safety and efficacy of drug eluting stents vs...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Safety and efficacy of drug eluting stents vs...